05:18 PM EDT, 07/08/2025 (MT Newswires) -- Emergent BioSolutions ( EBS ) said Tuesday it secured a $51.9 million contract modification to provide CNJ-016, also known as Vaccinia Immune Globulin Intravenous, to the US Administration for Strategic Preparedness and Response for smallpox preparedness.

The agency exercised an option under a 10-year contract to procure additional doses of CNJ-016, which is used to treat complications arising from smallpox vaccination, the company said.

The company's shares were rising nearly 4% in after-hours activity.